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Abstract
Endothelin (ET) 1 is important in the growth of prostate
cancer cells through the activation of the endothelin A
(ETA) receptor. ET receptor blockade is a new ther-
apeutic target in treating advanced prostate cancer.
This study investigates the impact of the combination
of the ETA antagonist atrasentan (ABT-627) and taxane
chemotherapy on prostate cancer cell survival in vitro
and on the delay of prostate cancer in a xenograft
mouse model. In vitro, PPC-1 cells transfected with an
ETA-overexpressing vector were treated with ABT-627,
paclitaxel/docetaxel, or both. Clonogenic viability and
cell death assays were used to determine cell survival
and apoptosis, respectively. ABT-627 and docetaxel
combination treatment was used in vivo to treat mice
with established ETA-overexpressing PPC-1 xenograft
tumors, and tumor growth rates were assessed. Cell
proliferation and vascularity were determined with
Ki-67 and CD31 staining, respectively. Cells treated
with combination therapy had significantly fewer viable
cells and more programmed cell death than cells given
monotherapy. Xenograft tumor growth rates were sig-
nificantly lower in mice treated with combination
therapy than in animals given a single agent. Ki-67
immunostaining demonstrated significantly fewer
proliferative cells following combination therapy than
following monotherapy. This study demonstrates ABT-
627 to have additive antitumor effects when used in
combination with taxane drugs both in vitro and in vivo.
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Introduction
Prostate cancer remains the second leading cause of
cancer-related deaths among males in the United States.
An averagemale carries an 18% lifetime risk of developing a
clinically apparent disease [1]. If detected early, localized
therapy, such as prostatectomy or radiation, can be cura-
tive; however, approximately 25% of patients with localized
disease experience biochemical recurrence following treatment
[2]. Initially, such men are treated with androgen deprivation to
induce apoptotic pathways, but the effects are typically short-
lived as patients develop androgen-refractory prostate cancer
(ARPC), followed by painful bone metastasis and death at a
median of 20 months following recurrence [3]. Unfortunately,
very little is known about the molecular mechanisms behind
advanced prostate cancer and the loss of androgen sensitivity.
As such, no curative therapy exists for ARPC.
In the treatment of advanced prostate cancer, one promising
target is the potent vasoconstrictor, endothelin (ET) 1. ET pep-
tides, which include ET-1, ET-2, and ET-3, work by binding to
endothelin A (ETA) and endothelin B (ETB) G-protein–coupled
seven-transmembrane receptors. Through interaction with
these receptors, ET peptides have been implicated in several
cancer-related processes, including nociception, tumor in-
vasion, neovascularization, osteogenesis, mitogenesis, and
apoptosis [4,5], in many solid organ malignancies, including
prostate cancer [6–14].
Accordingly, investigators have turned their attention to the
selective blockade of ETA receptors as a possible therapeutic
approach toward treating advanced prostate cancer. The
orally available atrasentan (ABT-627) potently (Ki = 34 pM)
and selectively (1862-fold) blocks the ETA receptor [15]. Al-
though prior studies have demonstrated a significant effect
of ABT-627 monotherapy on prostate cancer [16], the ETA
antagonist is likely to find its therapeutic niche as an agent
best used in combination with other chemotherapeutics, specifi-
cally the cytotoxic taxanes paclitaxel and docetaxel. Currently
the most effective Food and Drug Administration–approved
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treatment for advanced prostate cancer, the taxanes inhibit
microtubular depolymerization, thereby arresting cells in the
G2M phase of the cell cycle [1]. Preliminary xenograft studies
demonstrated that paclitaxel + ABT-627 combination therapy
significantly reduces tumor growth compared tomonotherapy
alone [17]. In an ovarian cancer model, Rosano et al. [18]
described a significant additive effect of taxane + ABT-627
on the reduction of tumor growth, apoptosis, and angiogen-
esis both in vivo and in vitro, further supporting the potential
of this combinational therapy. Given these encouraging
preliminary results, we set out to further investigate the role




Wild-type PPC-1 prostate cells transfected previously with
an ETA-overexpressing vector (pCMV-ETA) were grown in
RPMI 1640 supplemented with 10% fetal bovine serum
(GibcoBRL, Grand Island, NY) and 1% penicillin/strepto-
mycin. As negative controls, PPC-1 cells transfected with the
pCMV vector alone were grown under the same conditions.
Clonogenic Viability Assay
PPC-1-ETA and PPC-1-pCMV cells were each plated at a
density of 1.0  103 cells/well in six-well plates. Cells were
allowed to adhere overnight and were then pretreated with
either serum-free medium, ET-1 (107 M), ET-1 (107 M) +
ABT-627 ETA antagonist (10
6 M; Abbott Laboratories,
Abbott Park, IL), ET-1 (107 M) + A192621 ETB antagonist
(106 M; Abbott Laboratories), or ABT-627 (106 M) alone for
2 hours. Following pretreatment, serum-free medium, pacli-
taxel (107 M), or docetaxel (107 M) was added to each
of the conditions for 24 hours. Afterward, cells were given
fresh growth media and allowed to grow under normal con-
ditions. After 4 weeks, cells were washed with serum-free
medium, fixed, and stained with 0.1% crystal violet dissolved
in 20% methanol for 15 minutes. Plates were rinsed and
allowed to dry overnight. Colonies were counted in a blinded
fashion by three individuals and averaged; the results were
graphed and analyzed using GraphPad Prism3 (San Diego,
CA). Clonogenic assay was replicated in three separate
experiments for both docetaxel and paclitaxel.
Cell Death Detection
PPC-1-ETA cells were plated at a density of 2  104 cells/
well in 100-mm3 dishes. Cells adhered overnight and were
then pretreated with ET-1 (107M), serum-free medium, or
ABT-627 (106 M) for 2 hours. Afterward, cells were treated
for 24 hours with pretreatment conditions plus either pacli-
taxel (107 and 108 M), docetaxel (107 and 108 M), or
vehicle. Spectrophotometric enzyme-linked immunosorbent
assay (ELISA) was used to quantify histone-associated
DNA fragments present in cell lysates, according to the
manufacturer’s instructions (Roche Diagnostics, India-
napolis, IN). Briefly, the standard solution and samples were
added to the wells of a 96-well plate coatedwith amonoclonal
antibody. After incubation, the plate was washed, and an
enzyme-labeled antibody was added. After further incuba-
tion, the plate was washed again and treated with the
substrate, and optical density was determined at 405 nm
using an absorption spectrophotometer (Benchmark 680;
BioRad, Hercules, CA). Apoptosis assays were repeated in
three independent experiments.
Xenograft Studies
PPC-1-ETA cells were grown in culture in the above
conditions. When cells had reached 80% confluency, cells
were dissociated with trypsin and washed twice in Hank’s
balanced salt solution (HBSS), and 40 male athymic nu/nu
mice (Harlan Laboratories, Indianapolis, IN) received sub-
cutaneous flank injections of 5 105 cells per 100 ml of HBSS.
When the average tumor size had reached 0.05 cm3, themice
were given one of four drug treatments: 1) vehicle (ethanol,
i.p., every 3 days); 2) ABT-627 (20 mg/kg per day in drinking
water); 3) docetaxel (5 mg/kg, i.p., every 3 days); or 4) ABT-
627 (20 mg/kg per day in drinking water) + docetaxel (5 mg/
kg, i.p., every 3 days). Once the largest tumor burden had
reached 2 cm3, the mice were sacrificed and the tumors were
removed, measured, weighed, fixed in 4% paraformal-
dehyde, and embedded in paraffin for further analysis. Given
ET’s known role in angiogenesis, serum was also collected
for the quantification of vascular endothelial growth factor
(VEGF) by ELISA, in accordance with the manufacturer’s
instructions (R&D Systems, Minneapolis, MN).
Immunohistochemistry
Five-micron sections of paraffin-embedded tumors were
quenched in 3% hydrogen peroxide for 15 minutes and
stained following citrate-steam antigen retrieval with TEC-3
Ki-67 (M7249; Dako, Caripinteria, CA) and CD31 (SC-1506;
Santa Cruz Biotechnology, Santa Cruz, CA) primary anti-
bodies to determine cell proliferation and angiogenesis,
respectively. ETA and ETB polyclonal antibodies (Abbott
Laboratories) were also used to verify ET receptor expression
in xenograft tumors. A biotinylated secondary antibody was
used, followed by streptavidin-conjugated horseradish per-
oxidase and 3,3V-diaminobenzidine chromogen (K0690;
Dako). Slides were scored by three separate individuals in
a blinded fashion.
Tumor Pharmacokinetic Studies
Tumors were removed 12 hours after the administration of
docetaxel alone and in combination with ABT-627. Tumor
samples were obtained, weighed, frozen in liquid nitrogen,
and stored at 80jC until analysis. Tumor samples were
processed using a liquid– liquid extraction procedure fol-
lowed by solid-phase extraction, as previously described
[19]. Docetaxel concentrations in tumors were determined
by a liquid chromatography–mass spectrometry assay [20].
Statistical Analysis
All experimental data are representative of experiments
performed at least in triplicate. For statistical comparisons of
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groups, Graph Pad Prism software was used (Graph Pad
Software, San Diego, CA). For comparisons of values be-
tween groups, Student’s t test was used. Data are presented
as mean ± SE, and the level of significance was set at < .05
for all analyses.
Statistical Modeling
Tumor growth patterns in xenograft mice were assessed
using an exponential growth model (Y = baseline ea  time),
with the determination of doubling time for each treatment
(Doubling Time = 0.693 / a). This growth pattern served as
a template for determining growth parameters by nonlinear
mixed-effects modeling (NONMEM). Each treatment group
was assessed while preserving within-individual and
between-individual variances present in measurements of
tumor growth over time. In addition, the mixed-effects mod-
eling approach used every data point to determine growth
parameters, both as a mean and as a variance across indi-
viduals. Therefore, balance in the groups was not as critical
(weighting across individual contributions to this model is
based on data contributed, as well as on the informativeness
of data to a particular parameter). In mixed-effects modeling,
population average and variancewere calculated. In the case
of an exponential model, population average and variance
were based on the population average baseline tumor size
(S0) and a population average growth rate parameter (a).
Each treatment group was tested as a covariate in the
growth model to examine whether that group exhibited
unique growth characteristics. The threshold for determining
significance was based on the objective function returned by
the NONMEM software program, which is equal to 2 times
the log likelihood. The difference between nested models of
this objective function follows a chi-square distribution and
thus provides a means of statistically comparing growth
descriptions across models. The a level for significance was
set at .05, corresponding to an objective function change of
3.84 points for 1 df.
Results
Combination Therapy Yields Fewer Viable Cells Than
Does Monotherapy
Clonogenic studies of PPC-1-ETA cells demonstrated that
treatment with 107 M paclitaxel significantly decreased cell
viability (data not shown) (P = .0033). Figure 1D illustrates
that pretreatment of cells with 107 M ET-1 counteracted
the effects of paclitaxel. The addition of 106 M ABT-627, an
ETA antagonist, to ET-1 pretreatment blocked the ability of
ET-1 to protect cells from paclitaxel, significantly decreasing
the average number of colonies (P = .0438). Cells pretreated
with the ETB antagonist A192621, along with ET-1, remained
viable after paclitaxel administration (P = .4520) (data not
shown), suggesting that ET-1 mediates its protective effect
through the ETA receptor. This corroborates our earlier
findings that ETB receptor expression is absent in PPC-1
cells through the hypermethylation of ETB promoter region
EDNRB [21], and that ET-1 survival signaling works through
the ETA receptor using the phosphatidyinositol 3-kinase
(PI3-K) pathway [22,23].
Docetaxel treatment produced similar effects. Crystal
violet assessment of untreated and ET-1–treated groups
yielded too many colonies to be counted; the number of
viable cells was significantly decreased by the administration
of 108 M docetaxel alone. Cells pretreated with the ABT-627
ETA antagonist exhibited a significant decrease in viability
after docetaxel treatment when compared to docetaxel-
treated cells preincubated with ET-1 alone (P = .0338), il-
lustrating an additive effect of ETA blockade with docetaxel
(Figure 1D). Representative images of paclitaxel-treated
cell plates are shown above their respective treatment con-
ditions (Figure 1, A–C).
The efficacy of ABT-627 in both the presence and the
absence of ET-1 pretreatment suggests the presence of an
endogenous ET-1 ligand that promotes survival through the
ETA receptor—an observation consistent with our previously
published findings that prostate cancer cell lines, including
PPC-1, secrete significant levels of mature ET-1 [12]. Addi-
tionally, treatment of PPC-1-CMV control cells yielded results
similar to those of PPC-1-ETA (data not shown), suggesting
that PPC-1 cells expressed enough endogenous ETA re-
ceptors to yield a protective response.
Combination Therapy Results in More Apoptosis
To determine if the decrease in cell viability occurred
through an apoptotic mechanism, we used an ELISA-based
Figure 1. (A–C) ET-1 + ABT-627 + taxanes combination treatment resulted
in significantly fewer viable cells than treatment with taxanes alone. PPC-1
cells transfected with an ETA-overexpressing vector were pretreated with
vehicle, ET-1, ET-1 + ABT-627 ETA antagonist, or ET-1 + A192621 ETB
antagonist, followed by treatment with paclitaxel or docetaxel. Crystal violet
analysis was performed after 3 weeks to determine cell survival after
treatments: (A) docetaxel, (B) docetaxel + ET-1, and (C) docetaxel + ABT-
627 + ET-1. Results are reported as the mean of the number of colonies ± SE
from three independent experiments. (D) ET-1 increased the number of
colonies in docetaxel-treated and paclitaxel-treated PPC-1 cells. Blocking the
ETA receptor with ABT-627 significantly reduced cell survival. Results are
reported as the mean of the number of colonies ± SE from three independent
experiments (P < .05).
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assay tomeasureDNA fragmentation in PPC-1-ETA cells that
had undergone various treatments. Treatment with ABT-627
significantly increased the number of apoptotic cells (P =
.044) (Figure 2). As monotherapy, administration of 107
and 108 M paclitaxel and of 107 and 108 M docetaxel
also significantly increased cell death in a dose-dependent
fashion (P < .0001, .0001, .0001, and .045, respectively).
Coadministration of 106 M ABT-627, however, significantly
increased the amount of cell death following 107Mpaclitaxel
(P = .0094) and 108 M docetaxel (P = .02), respectively, over
treatment with the corresponding taxane monotherapy. How-
ever, this significance of ABT-627 combination therapy was
not present following lower-dose paclitaxel or higher-dose
docetaxel, suggesting a specific therapeutic window in which
combination therapy is most effective. Overall, these in vitro
results demonstrate an additive effect of ABT-627 and cyto-
toxic taxane therapy on apoptosis. These data suggest that,
for in vivo studies, docetaxel can be used at a dose lower than
that of paclitaxel in combination with ABT-627 to effectively
reduce tumor volume.
Combination Therapy Reduces Xenograft Growth Rates
More Than Does Monotherapy
The efficacy of low-dose docetaxel monotherapy versus
ABT-627 + docetaxel combination therapy was assessed
in vivo using a xenograft mousemodel. Athymicmice bearing
established PPC-1-ETA xenograft tumors were treated with
vehicle, ABT-627 alone, docetaxel alone, or ABT-627 +
docetaxel. Figure 3 illustrates the tumor volumes of these
mice over the treatment period. Mice treated with vehicle
had the same tumor burdens as those treated with either
ABT-627 or docetaxel monotherapy. However, mice given
the combination therapy had significantly smaller tumor vol-
umes than mice in the other treatment groups. Note that, at
the end of the experiment, all mice treated with vehicle or
ABT-627 remained alive; in contrast, 6 of 9 mice treated with
docetaxel and 5 of 10 mice given the combination therapy
survived. This was most likely secondary to the toxic effects
of drug accumulation following seven doses of docetaxel.
A tumor growth mathematical model was used to more
accurately assess tumor growth patterns in xenograft mice
(Table 1). Using an exponential growth model, only the
combination treatment group displayed a tumor growth rate
distinguishable from those of the other groups. The combi-
nation treatment group had a tumor doubling time of 8.7 days
(12.1% coefficient of variation), whereas the other groups all
had a tumor doubling time of 5.8 days (25.8% coefficient of
variation). The use of a separate growth rate for the combi-
nation treatment group improved the description of the data
(P = .0045, v2 = 8, df = 1).
Combination Therapy Significantly Decreases Tumor Cell
Proliferation, But Not Vascularity
Xenograft tumors were immunostained with Ki-67 and
CD31 antibodies to illustrate cell proliferation and tumor
vascularity, respectively. Positive cells were counted and
averaged between three individuals. Figure 4I illustrates that
tumors ofmice treatedwith ABT-627 + docetaxel combination
therapy had significantly fewer proliferative cells than tu-
mors of mice treated with either vehicle, ABT-627 alone, or
docetaxel alone (P = .0225, .0031, and .0457, respectively).
Representative images of Ki-67–stained tumors are illus-
trated in Figure 4, A, C, E, and G.
In contrast, CD31 staining illustrated no significant differ-
ence between treatment groups (data not shown). Repre-
sentative images of xenograft tumors stained with CD31
demonstrate no significant difference in tumor vascularity
Figure 2. Combination treatment with ABT-627 + paclitaxel or docetaxel
resulted in significantly more cell deaths than treatment with taxane alone.
Prostate cancer cells were pretreated with serum-free medium, ET-1, or ABT-
627 ETA antagonist, followed by treatment with vehicle, 10 nM paclitaxel,
100 nM paclitaxel, 10 nM docetaxel, or 100 nM docetaxel. Apoptosis was
quantified with a spectrophotometric ELISA-based assay. Results are reported
as the mean ± SE from three independent experiments (P < .05).
Figure 3.Mice treated with combination ABT-627 + docetaxel had significantly
smaller tumor burdens and growth rates than mice treated with vehicle,
ABT-627, or docetaxel alone. ETA-overexpressing PPC-1 cells were injected
as xenograft tumors in athymic mice. Mice with established tumors were
treated with vehicle, docetaxel, ABT-627 ETA antagonist, or a combination of
docetaxel + ABT-627. Tumors were measured every 2 days. Results are
reported as mean tumor size ± SE.
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following monotherapy or combination therapy. Serum was
also harvested from xenograft mice and analyzed for VEGF
levels by ELISA. Similar to CD31 data, ELISA revealed no
significant difference in VEGF levels between mice in any of
the treatment groups (data not shown). Analysis of ETA
expression in the tumors demonstrated that receptor levels
remained high in all treatment groups, suggesting that selec-
tion for subpopulations of PPC-1 cells with altered ETA
expression did not contribute to the change in tumor vol-
ume with combination therapy (data not shown). ETB re-
ceptor expression was not detectable in prostate tumor
cells, whereas endothelial cells of the tumor vasculature
were used as internal controls and were positive for ETB ex-
pression in all treatment groups.
Combination Treatment Does Not Significantly Change
Tissue Docetaxel Concentration
Given ET’s vasoactive properties, LC/MS analysis was
performed to determine whether tissue concentrations of
docetaxel increased with coadministration of ABT-627. The
average tumor concentration of docetaxel in mice treated
with docetaxel monotherapy was 110.7 ± 53.26 nM. Mice
treated with combination therapy had a slightly decreased
tumor docetaxel concentration of 16.33 ± 13.33 nM, but this
difference was not significant (P = .0843).
Discussion
The normal prostate expresses both ET receptors [24].
Luminal epithelial cells secrete ET-1 [25], which is normally
found in greatest concentration within the ejaculate of both
intact and vasectomized men [26]. Although its physio-
logical role in the prostate has yet to be determined, ET
involvement in neoplastic transformation is becoming evi-
dent. ET-1 activation of ETA receptors localized on pros-
tate stromal cells has antiapoptotic effects. Earlier studies
from our laboratory have shown that ETA/ET-1 receptor–
ligand binding correlates with a time-dependent and dose-
dependent activation of PI3-K, leading to phosphorylation of
AKT and the subsequent inactivation of the proapoptotic
protein, Bad [23]. In addition, prostate tumor cell exposure
to ET-1 decreases the overall expression of Bad, as well as
of the other proapoptotic proteins Bak and Bax. In contrast,
activation of the ETB receptors found within epithelial lu-
minal cells counteracts ETA by inducing both apoptotic and
ET-1 clearance pathways. Studies have shown that re-
expression of ETB may increase apoptosis through an in-
creased expression of the same proapoptotic proteins Bad,
Bak, and Bax [23].
Figure 4. Mice treated with combination therapy had significantly fewer
proliferative cells than those given monotherapy or vehicle alone. Tumor
vascularity was not affected. ETA-overexpressing PPC-1 xenograft tumors
were grown in athymic mice treated with vehicle, docetaxel, ABT-627 ETA, or
a combination of docetaxel + ABT-627. After 21 days of treatment, tumors
were removed and analyzed by immunohistochemistry for Ki-67 (for the
evaluation of cell proliferation) and CD31 (for tumor vasculature analysis)
expression. (A and B) Vehicle, (C and D) ABT-627, (E and F) docetaxel,
(G and H) ABT-627 + docetaxel, and (I) Ki-67+ cells were quantified in each
tumor section. Combination therapy reduced tumor cell proliferation relative
to vehicle-treated or monotherapy-treated mice (P < .05). In contrast, CD31
staining remained unchanged with treatment.








Vehicle 63.73 690.5 ± 165.0 5.93
ABT-627 54.58 775.5 ± 164.2 5.36
Docetaxel 55.57 657.4 ± 158.3 5.41
ABT-627 + docetaxel 55.1 321.7 ± 76.1* 8.29*
*Statistically different from all other treatment groups (P < .05).
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ET receptor expression is altered in prostate cancer.
Although ETA receptor expression increases with disease
aggressiveness [27], ETB receptor levels decrease. The
decrease in ETB results, in part, from the hypermethyla-
tion of the EDNRB promoter region [21]. Hypermethylation
correlates with the grade and the stage of prostate cancer
[28,29]. EDNRB promoter methylation leads to a decrease
in ETB-induced ET-1 clearance. Advanced prostate cancer
also corresponds with a decreased activity of the ET-1–
cleaving enzyme, neutral endopeptidase 24.11 (NEP) [30].
Given these observations, it is not surprising that patients
with ARPC have greater serum ET-1 levels than those with
localized disease or than those with no disease [12]. This
suggests a prostate cancer model in which the decreased
expression of NEP and ETB results in increased ET-1 levels
and uninhibited ETA activation, culminating in the promotion
of carcinogenic pathways.
In addition to its effects on apoptosis, the ETaxis has also
been implicated in mitogenesis through the activation of the
protein kinase C, PI3-K, and MAP kinase signaling pathways
[31].Within a prostate cancermodel, ET-1 has been shown to
induce the proliferation of prostate cancer cells, especially
when used synergistically with polypeptide growth factors
such as epidermal growth factor [32]. This mitogenic effect
also occurs in osteoblasts—the bone-forming cells respon-
sible for painful bone lesions characteristic of advanced
prostate cancer. With approximately 104 ETA receptors per
cell, osteoblasts have a surprisingly high density of receptors
[33]. In vitro studies have shown that ET-1 both induces
osteoblastic bone proliferation and inhibits osteoclastic bone
resorption; in a murine model, the administration of a selec-
tive ETA receptor antagonist significantly attenuates this
effect [34,35]. In addition to the inhibitory potency of ET-1
in osteoclast bone resorption, there is a concentration-
dependent reduction in osteoclast motility at nanomolar
levels of ligand [36]. ET-1 produced by marrow endothelial
cells, as well as prostate tumor cells residing in the bone, will
have important roles in the local regulation of osteoclast
function. In ovarian cancer models, ET-1 induces VEGF
and other angiogenic factors as well, leading to tumor neo-
vascularization [37]; however, our present study did not de-
tect a significant effect of ETA blockade on tumor vascularity
or serum VEGF.
Our data showed that the combination of ETA antagonism
and cytotoxic taxane therapy is significantly more efficacious
than treatment with either modality alone. In vitro, both
paclitaxel and docetaxel, when combined with ABT-627,
had additive effects on both decreasing cell viability and
increasing apoptosis in PPC-1 cells. In vivo, ABT-627 and
docetaxel combination therapy significantly reduced the rate
of growth of xenograft tumors more than did monotherapy.
Furthermore, Ki-67 staining of xenograft tumors illustrated
that combination therapy attenuated the number of prolifer-
ating cells significantly more than treatment with either doce-
taxel or ABT-627 alone.
Additive effects can be explained mechanistically; al-
though both drugs activate the proapoptotic proteins of
the Bcl-2 family, each has distinct nonoverlapping anti-
carcinogenic mechanisms. The taxanes primarily inhibit
microtubular depolymerization, whereas ABT-627 blocks
ETA-associated proliferative and antiapoptotic pathways
[22,23]. Taxanes also work by decreasing Bcl-2 binding to
Bax—the same proapoptotic protein inhibited by ET-1 [38].
Given ET’s vasoactive properties, it would be reasonable
to assume that the increased effectiveness of combination
therapy would be due to ABT-627–mediated vascular
changes. However, serum VEGF analysis and CD31 vascu-
lar endothelium labeling of xenograft tumor demonstrated
no differences between mice in the different treatment
groups. Additionally, xenograft tumors illustrated no differ-
ence in docetaxel concentrations following ETA blockade.
Thus, it appears that ABT-627–mediated enhanced cytotox-
icity was not due to changes in blood flow or vascularity. Prior
studies have shown ET-1 to increase blood flow in a breast
cancer model through the activation of the ETB receptor [39];
our results suggest that ETA blockade does not have similar
effects in a prostate cancer model. However, in this study, we
examined concentrations at a single time point 12 hours after
the last of seven docetaxel doses. A pharmacokinetic study to
further examine docetaxel distribution in tumors at serial time
points with and without ABT-627 would provide a more
complete picture of the role of ETA blockade in reducing
tumor growth with combination therapy.
Prostate cancer is characterized by low rates of prolifera-
tion, making it resistant to most forms of cytotoxic chemo-
therapy. Prostate cancer chemotherapy is not curative; in a
recent phase III clinical study, the SouthwestOncologyGroup
reported that treatment of ARPC with docetaxel + estramus-
tine increased disease survival by only 3 months in patients
who received only mitoxantrone with prednisone [40]. As
such, the demand for new treatments remains high. With
implicated roles in tumor cell survival, apoptosis, mito-
genesis, neovascularization, and osteogenesis, the ET axis
is well suited for therapeutic manipulation. Initially designed
as an antihypertensive, the ETA antagonist ABT-627 has a
half-life of 25 hours, making it ideally suited for long-term
once-daily dosing. Adverse effects are mild and correspond
with the drug’s vasoactive properties, including headache,
rhinitis, and peripheral edema [4].
As monotherapy, ABT-627 has already been well-studied
clinically. Following encouraging phase I and II studies
[16,41,42], recent phase III clinical trials have focused on
the efficacy of ABT-627 in combating ARPC. These studies
assessed time to disease progression, prostate-specific an-
tigen progression, bone metabolism markers, and quality of
life in prostate cancer patients given ABT-627 vs placebo.
Although the first completed set of these trials demonstrated
that ABT-627 both significantly delayed disease progression
and attenuated the increase in bone and tumormarkers in the
evaluable population, the drug did not significantly delay
disease progression in the intent-to-treat population. Al-
though the lack of a significant effect for ABT-627 mono-
therapy in this first phase III trial was disappointing, a
therapeutic effect from treatment clearly exists.
In light of these clinical results, our study supports the
hypothesis that ABT-627 may have greater clinical utility
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when used in combination with taxane treatment. Ongoing
phase I clinical studies are already examining ABT-627 +
docetaxel combination therapy in patients with advanced
disease. Although the results of these trials have yet to be
published, it will be of great interest to see if clinical studies
confirm our results. Although our data support the concept
that ABT-627 has additive effects on treating advanced
prostate cancer with the cytotoxic taxanes, further studies
are necessary to optimize the combination to evoke the
most effective therapeutic response. Only then will we be
able to determine the full therapeutic potential of ET manip-
ulation in the treatment of advanced prostate cancer.
Conclusion
The ET axis is involved in several tumorigenic pathways in
prostate cancer. Both in vitro and in vivo, blockade of the ETA
receptor with ABT-627 demonstrated significant additive
effects when used in combination with the cytotoxic taxanes
paclitaxel and docetaxel. Given the efficacy, low toxicity
profile, bioavailability, and half-life of ABT-627, additional
studies should be performed to further delineate the thera-
peutic role of this promising agent.
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